Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: More than 15 years have passed since the first description of the unbound brain-to-plasma partition coefficient (K p,uu,brain ) by Prof. Margareta Hammarlund-Udenaes, which was enabled by advancements in experimental methodologies including cerebral microdialysis. Since then, growing knowledge and data continue to support the notion that the unbound (free) concentration of a drug at the site of action, such as the brain, is the driving force for pharmacological responses. Towards this end, K p,uu,brain is the key parameter to obtain unbound brain concentrations from unbound plasma concentrations. Methods: To understand the importance and impact of the K p,uu,brain concept in contemporary drug discovery and development, a survey has been conducted amongst major pharmaceutical companies based in Europe and the USA. Here, we present the results from this survey which consisted of 47 questions addressing: 1) Background information of the companies, 2) Implementation, 3) Application areas, 4) Methodology, 5) Impact and 6) Future perspectives. Results and conclusions: From the responses, it is clear that the majority of the companies (93%) has established a common understanding across disciplines of the concept and utility of K p,uu,brain as compared to other parameters related to brain exposure. Adoption of the K p,uu,brain concept has been mainly driven by individual scientists advocating its application in the various companies rather than by a top-down approach. Remarkably, 79% of all responders describe the portfolio impact of K p,uu,brain implementation in their companies as ‘game-changing’. Although most companies (74%) consider the current toolbox for K p,uu,brain assessment and its validation satisfactory for drug discovery and early development, areas of improvement and future research to better understand human brain pharmacokinetics/pharmacodynamics translation have been identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Shawahna, R., Uchida, Y., Declèves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P.-O., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200129p · Cited by 372
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Improved measurement of drug exposure in the brain using drug-specific correction for residual blood
Fridén, M., Ljungqvist, H., Middleton, B., Bredberg, U., & Hammarlund-Udenaes, M. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.200 · Cited by 114
Self-citationSchmitt, M. V., Reichel, A., Liu, X., Fricker, G., & Lienau, P. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000161 · Cited by 19
Self-citation
Research works printed but not linked: 155
- Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos. 2006;34(2):318–23. · DOI
- Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737–50. · DOI · Paper page
- Kalant H. A microdialysis procedure for extraction and isolation of corticosteroids from peripheral blood plasma. Biochem J. 1958;69(1):99–103. · doi:10.1042/bj0690099
- Gaddum JH. Push-pull cannulae. J Physiol. 1961;155(suppl):1–28. · doi:10.1113/jphysiol.1961.sp006651
- Bito L, Davson H, Levin E, Murray M, Snider N. The concentrations of free amino acids and other electrolytes in cerebrospinal fluid, in vivo dialysate of brain, and blood plasma of the dog. J Neurochem. 1966;13(11):1057–67. · DOI · Paper page
- Codd AA. A simple device for microdialysis. J Clin Pathol. 1968;21(1):113–4. · doi:10.1136/jcp.21.1.113
- Brand PH, Stansbury R. Improved microdialysis technique. Anal Biochem. 1979;94(1):109–11. · doi:10.1016/0003-2697(79)90798-x
- Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. J Clin Invest. 1979;64(1):145–54. · DOI · Paper page
- Benveniste H, Huttemeier PC. Microdialysis–theory and application. Prog Neurobiol. 1990;35(3):195–215. · DOI · Paper page
- Ekblom M, Hammarlund-Udenaes M, Lundqvist T, Sjoberg P. Potential use of microdialysis in pharmacokinetics: a protein binding study. Pharm Res. 1992;9(1):155–8. · doi:10.1023/a:1018960617549
- Elmquist WF, Sawchuk RJ. Application of microdialysis in pharmacokinetic studies. Pharm Res. 1997;14(3):267–88. · DOI · Paper page
- Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev. 2000;45(2–3):283–94. · doi:10.1016/s0169-409x(00)00109-5
- Dubey RK, McAllister CB, Inoue M, Wilkinson GR. Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. J Clin Invest. 1989;84(4):1155–9. · doi:10.1172/jci114279
- Ekblom M, Gardmark M, Hammarlund-Udenaes M. Estimation of unbound concentrations of morphine from microdialysate concentrations by use of nonlinear regression analysis in vivo and in vitro during steady state conditions. Life Sci. 1992;51(6):449–60. · doi:10.1016/0024-3205(92)90413-j
- Ekblom M, Gardmark M, Hammarlund-Udenaes M. Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. Biopharm Drug Dispos. 1993;14(1):1–11. · doi:10.1002/bdd.2510140102
- Wang Y, Welty DF. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm Res. 1996;13(3):398–403. · DOI
- Xie R, Hammarlund-Udenaes M. Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res. 1998;15(4):570–5. · DOI
- Bouw R, Ederoth P, Lundberg J, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M. Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. Acta Anaesthesiol Scand. 2001;45(3):390–2. · DOI
- Ederoth P, Tunblad K, Bouw R, Lundberg CJ, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol. 2004;57(4):427–35. · DOI
- Tunblad K, Ederoth P, Gardenfors A, Hammarlund-Udenaes M, Nordstrom CH. Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand. 2004;48(3):294–301. · doi:10.1111/j.0001-5172.2003.0311.x
- Bostrom E, Simonsson US, Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos. 2006;34(9):1624–31. · DOI · Paper page
- Bundgaard C, Jorgensen M, Mork A. An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. J Pharmacol Toxicol Methods. 2007;55(2):214–23. · DOI
- Harashima H, Sugiyama Y, Sawada Y, Iga T, Hanano M. Comparison between in-vivo and in-vitro tissue-to-plasma unbound concentration ratios (Kp, f) of quinidine in rats. J Pharm Pharmacol. 1984;36(5):340–2. · DOI
- Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos. 2007;35(9):1711–9. · DOI · Paper page
- Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem. 2009;52(20):6233–43. · DOI · Paper page
- Ooie T, Terasaki T, Suzuki H, Sugiyama Y. Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos. 1997;25(7):784–9.
- Donnan FG. The theory of membrane equilibria. Chem Rev. 1924;1(1):73–90. · DOI · Paper page
- Klotz IM. The application of the law of mass action to binding by proteins; interactions with calcium. Arch Biochem. 1946;9:109–17.
- Zwolinski BJ, Eyring H, Reese CE. Diffusion and membrane permeability. I. J Phys Colloid Chem. 1949;53(9):1426–53. · DOI
- Staverman AJ. Non-equilibrium thermodynamics of membrane processes. Trans Faraday Soc. 1952;48:176–85. · DOI · Paper page
- Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother. 1956;11(4):379–93. · DOI · Paper page
- Schanker LS. Passage of drugs across body membranes. Pharmacol Rev. 1962;14:501–30.
- Bartels E, Podleski TR. Action of nicotine on the electroplax and difference of potency between ionized and unionized forms. BBA - Specialised Section on Biophysical Subjects. 1964;79(3):511–20.
- Fenstermacher J, Kaye T. Drug diffusion within the brain. Ann NY Acad Sci. 1988;531:29–39. · DOI · Paper page
- Fichtl B, Nieciecki AV, Walter K. Tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. In: Testa B, editor. Advances in Drug Research, vol. 20. Academic Press; 1991. p. 117–66.
- Hammarlund-Udenaes M, Paalzow LK, de Lange EC. Drug equilibration across the blood-brain barrier–pharmacokinetic considerations based on the microdialysis method. Pharm Res. 1997;14(2):128–34. · DOI · Paper page
- Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929–39. · DOI · Paper page
- Tillement J-P, Urien S, Chaumet-Riffaud P, Riant P, Bree F, Morin D, Albengres E, Barre J. Blood binding and tissue uptake of drugs Recent advances and perspectives. Fundam Clin Pharmacol. 1988;2(S1):72–87. · doi:10.1111/j.1472-8206.1988.tb00663.x
- Bouw MR, Gardmark M, Hammarlund-Udenaes M. Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats–a microdialysis study. Pharm Res. 2000;17(10):1220–7. · DOI
- Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002;23(8):327–38. · DOI · Paper page
- Mano Y, Higuchi S, Kamimura H. Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos. 2002;23(9):351–60. · DOI
- Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos. 2007;35(4):660–6. · DOI · Paper page
- Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos. 2009;37(7):1548–56. · DOI · Paper page
- Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. Receptor occupancy and brain free fraction. Drug Metab Dispos. 2009;37(4):753–60. · DOI
- Hammarlund-Udenaes M. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol. 2010;106(3):215–20. · DOI
- Gupta A, Gillard M, Christophe B, Chatelain P, Massingham R, Hammarlund-Udenaes M. Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. Br J Pharmacol. 2007;151(7):1129–36. · DOI
- Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and pharmacodynamics of seven opioids in p-glycoprotein-competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther. 2007;323(1):346–55. · DOI · Paper page
- Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology. 2008;108(3):495–505. · DOI · Paper page
- Bundgaard C, Sveigaard C, Brennum LT, Stensbol TB. Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: the role of free drug concentrations. Xenobiotica. 2012;42(3):256–65. · DOI
- Kahlenberg L. On the nature of the process of osmosis and osmotic pressure with observations concerning dialysis. J Phys Chem. 1905;10(3):141–209. · doi:10.1021/j150075a001
- Davis BD, Wood WB Jr. Studies on antibacterial action of sulfonamide drugs. III. Correlation of drug activity with binding to plasma proteins. Proc Soc Exp Biol Med. 1942;51(2):283–5. · doi:10.3181/00379727-51-13938
- Hamilton PB, Archibald RM. Dialysis cell for rapid quantitative analytical determination of diffusible components in blood plasma. Ind Eng Chem Anal Ed. 1944;16(2):136–7. · doi:10.1021/i560126a025
- Klotz IM. Spectrophotometric investigations of the interactions of proteins with organic anions. J Am Chem Soc. 1946;68(11):2299–304. · DOI
- Kurz H, Trunk H, Weitz B. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung. 1977;27(7):1373–80.
- Kariv I, Cao H, Oldenburg KR. Development of a high throughput equilibrium dialysis method. J Pharm Sci. 2001;90(5):580–7. · DOI
- Lin TH, Lin JH. Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J Pharmacol Exp Ther. 1990;253(1):45–50. · DOI
- Romer J, Bickel MH. A method to estimate binding constants at variable protein concentrations. J Pharm Pharmacol. 1979;31(1):7–11. · DOI
- Kurz H, Fichtl B. Binding of drugs to tissues. Drug Metab Rev. 1983;14(3):467–510. · doi:10.3109/03602538308991397
- Summerfield SG, Stevens AJ, Cutler L, del Carmen OM, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther. 2006;316(3):1282–90. · DOI · Paper page
- Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50(19):4606–15. · DOI · Paper page
- Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37(4):787–93. · DOI · Paper page
- Wan H, Ahman M, Holmen AG. Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. J Med Chem. 2009;52(6):1693–700. · DOI
- Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE. Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos. 2011;39(7):1270–7. · DOI
- Reichel A. Integrated approach to optimizing CNS penetration in drug discovery: from the old to the new paradigm and assessment of drug-transporter interactions. In: Hammarlund-Udenaes M, de Lange ECM, Thorne RG, editors. Drug delivery to the brain: physiological concepts, methodologies and approaches. New York: Springer, New York; 2014. p. 339–74. · DOI
- Di L, Rong H, Feng B. Demystifying brain penetration in central nervous system drug discovery. J Med Chem. 2013;56(1):2–12. · DOI · Paper page
- Van Peer AP, Belpaire FM, Bogaert MG. Binding of drugs in serum, blood cells and tissues of rabbits with experimental acute renal failure. Pharmacology. 1981;22(2):146–52. · doi:10.1159/000137483
- Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther. 1996;277(3):1550–9.
- Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos. 2009;37(6):1226–33. · DOI
- Loryan I, Friden M, Hammarlund-Udenaes M. The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS. 2013;10(1):6. · DOI · Paper page
- Becker S, Liu X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos. 2006;34(5):855–61. · DOI
- Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39(3):353–62. · DOI · Paper page
- Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg W, Vermeulen A, Morrison D, Monshouwer M, Heald D, Hammarlund-Udenaes M. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery. Pharm Res. 2014;31(8):2203–19. · DOI
- Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther. 2011;339(3):935–44. · DOI
- Liu X, Ding X, Deshmukh G, Liederer BM, Hop CE. Use of cassette dosing approach to assess brain penetration in drug discovery. Drug Metab Dispos. 2012;40:963–9. · DOI
- Loryan I, Melander E, Svensson M, Payan M, Konig F, Jansson B, Hammarlund-Udenaes M. In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy. Mol Psychiatry. 2016;21(11):1527–36. · DOI
- Colclough N, Chen K, Johnström P, Fridén M, McGinnity DF. Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery. Drug Discovery Today. 2019;24(5):1067–73. · DOI
- Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018;4(6):eaat1719. · DOI · Paper page
- Shaffer CL, Osgood SM, Mancuso JY, Doran AC. Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. J Pharm Sci. 2014;103(5):1557–62. · DOI
- Liu H, Chen Y, Huang L, Sun X, Fu T, Wu S, Zhu X, Zhen W, Liu J, Lu G, Cai W, Yang T, Zhang W, Yu X, Wan Z, Wang J, Summerfield SG, Dong K, Terstappen GC. Drug distribution into peripheral nerve. J Pharmacol Exp Ther. 2018;365(2):336–45. · DOI
- Doran AC, Osgood SM, Mancuso JY, Shaffer CL. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos. 2012;40(11):2162–73. · DOI
- Schou M, Varnäs K, Lundquist S, Nakao R, Amini N, Takano A, Finnema SJ, Halldin C, Farde L. Large variation in brain exposure of reference CNS drugs: a PET study in nonhuman primates. Int J Neuropsychopharmacol. 2015;18(10):pyv036. · DOI
- Gustafsson S, Eriksson J, Syvanen S, Eriksson O, Hammarlund-Udenaes M, Antoni G. Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations. Neuroimage. 2017;155:177–86. · DOI
- Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab. 2012;32(5):874–83. · DOI
- Jucaite A, Stenkrona P, Cselényi Z, De Vita S, Buil-Bruna N, Varnäs K, Savage A, Varrone A, Johnström P, Schou M, Davison C, Sykes A, Pilla Reddy V, Hoch M, Vazquez-Romero A, Moein MM, Halldin C, Merchant MS, Pass M, Farde L. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study. Neuro Oncol. 2021;23(4):687–96. · DOI
- Friden M, Wennerberg M, Antonsson M, Sandberg-Stall M, Farde L, Schou M. Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain. EJNMMI Res. 2014;4(1):50. · DOI
- Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD. Toward an improved prediction of human in vivo brain penetration. Xenobiotica. 2008;38(12):1518–35. · DOI
- Assmus F, Seelig A, Gobbi L, Borroni E, Glaentzlin P, Fischer H. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. Eur J Pharm Sci. 2015;79:27–35. · DOI
- Luptakova D, Vallianatou T, Nilsson A, Shariatgorji R, Hammarlund-Udenaes M, Loryan I, Andren PE. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. Mol Psychiatry. 2021;26:7732–45. · DOI
- Liu H, Dong K, Zhang W, Summerfield SG, Terstappen GC. Prediction of brain:blood unbound concentration ratios in CNS drug discovery employing in silico and in vitro model systems. Drug Discov Today. 2018;23(7):1357–72. · DOI
- Dolgikh E, Watson IA, Desai PV, Sawada GA, Morton S, Jones TM, Raub TJ. QSAR model of unbound brain-to-plasma partition coefficient, Kp, uu, brain: incorporating P-glycoprotein efflux as a variable. J Chem Inf Model. 2016;56(11):2225–33. · DOI
- Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg WH, Vermeulen A, Heald D, Hammarlund-Udenaes M, Wassvik CM. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol Pharm. 2015;12(2):520–32. · DOI
- Chen H, Winiwarter S, Friden M, Antonsson M, Engkvist O. In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms. J Mol Graph Model. 2011;29(8):985–95. · DOI
- Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58(6):2584–608. · DOI · Paper page
- Li Y, Terstappen GC, Zhang W. Differentiation of human induced pluripotent stem cells (hiPSC) into endothelial-type cells and establishment of an in vitro blood-brain barrier model. Methods Mol Biol. 2021. · DOI
- Chaves C, Do TM, Cegarra C, Roudieres V, Tolou S, Thill G, Rocher C, Didier M, Lesuisse D. Non-human primate blood-brain barrier and in vitro brain endothelium: from transcriptome to the establishment of a new model. Pharmaceutics. 2020;12(10):967. · DOI
- Heymans M, Sevin E, Gosselet F, Lundquist S, Culot M. Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration. Eur J Pharm Biopharm. 2018;127:453–61. · DOI
- Feng B, Doran AC, Di L, West MA, Osgood SM, Mancuso JY, Shaffer CL, Tremaine L, Liras J. Prediction of human brain penetration of P-glycoprotein and breast cancer resistance protein substrates using in vitro transporter studies and animal models. J Pharm Sci. 2018;107(8):2225–35. · DOI
- Cecchelli R, Aday S, Sevin E, Almeida C, Culot M, Dehouck L, Coisne C, Engelhardt B, Dehouck MP, Ferreira L. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS One. 2014;9(6):e99733. · DOI · Paper page
- Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck M-P, Fenart L. Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discovery. 2007;6(8):650–61. · DOI · Paper page
- Reichel A, Begley DJ, Abbott NJ. An overview of in vitro techniques for blood-brain barrier studies. Methods Mol Med. 2003;89:307–24.
- Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. The critical role of passive permeability in designing successful drugs. ChemMedChem. 2020;15(20):1862–74. · DOI
- Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther. 2005;313(3):1254–62. · DOI · Paper page
- Culot M, Fabulas-da Costa A, Sevin E, Szorath E, Martinsson S, Renftel M, Hongmei Y, Cecchelli R, Lundquist S. A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. PLoS One. 2013;8(12):e80634. · DOI
- Trapa PE, Belova E, Liras JL, Scott DO, Steyn SJ. Insights from an integrated physiologically based pharmacokinetic model for brain penetration. J Pharm Sci. 2016;105(2):965–71. · DOI
- Ozgür B, Saaby L, Janfelt C, Langthaler K, Eneberg E, Jacobsen A-M, Badolo L, Montanari D, Brodin B. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: in vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice. Eur J Pharm Biopharm. 2021;169:211–9. · doi:10.1016/j.ejpb.2021.10.006
- Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, Terasaki T. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-Glycoprotein substrates in cynomolgus monkeys. J Pharmacol Exp Ther. 2014;350(3):578–88. · DOI
- Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36(2):268–75. · DOI · Paper page
- Sato S, Matsumiya K, Tohyama K, Kosugi Y. Translational CNS steady-state drug disposition model in rats, monkeys, and humans for quantitative prediction of brain-to-plasma and cerebrospinal fluid-to-plasma unbound concentration ratios. AAPS J. 2021;23(4):81. · DOI
- He H, Lyons KA, Shen X, Yao Z, Bleasby K, Chan G, Hafey M, Li X, Xu S, Salituro GM, Cohen LH, Tang W. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure. Xenobiotica. 2009;39(9):687–93. · DOI
- Vendel E, Rottschäfer V, de Lange ECM. The need for mathematical modelling of spatial drug distribution within the brain. Fluids Barriers CNS. 2019;16(1):12–12. · DOI
- Yamamoto Y, Valitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Bakshi S, Aranzana-Climent V, Marchand S, Dahyot-Fizelier C, Couet W, Danhof M, van Hasselt JG, de Lange EC. A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. Pharm Res. 2017;34(2):333–51. · DOI
- Yamamoto Y, Valitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM. Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model. CPT Pharmacometrics Syst Pharmacol. 2017;6(11):765–77. · DOI
- Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J. 2012;14(3):543–53. · DOI
- Westerhout J, Danhof M, De Lange EC. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci. 2011;100(9):3577–93. · DOI
- Lin JH, Sugiyama Y, Awazu S, Hanano M. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm. 1982;10(6):637–47. · DOI
- Gardmark M, Hammarlund-Udenaes M. Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat–pharmacokinetic/pharmacodynamic modelling. Pain. 1998;74(2–3):287–96. · doi:10.1016/s0304-3959(97)00180-2
- Gardmark M, Karlsson MO, Jonsson F, Hammarlund-Udenaes M. Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling J Pharm Sci. 1998;87(7):813–20. · doi:10.1021/js980056f
- Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol. 1999;128(3):563–8. · DOI · Paper page
- Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats–pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol. 2001;134(8):1796–804. · doi:10.1038/sj.bjp.0704406
- Gupta A, Jansson B, Chatelain P, Massingham R, Hammarlund-Udenaes M. Quantitative determination of cetirizine enantiomers in guinea pig plasma, brain tissue and microdialysis samples using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(12):1749–57. · doi:10.1002/rcm.1983
- Gupta A, Hammarlund-Udenaes M, Chatelain P, Massingham R, Jonsson EN. Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. Biopharm Drug Dispos. 2006;27(6):291–7. · DOI
- Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34(9):1443–7. · DOI · Paper page
- Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab. 2006;7(2):183–203. · DOI · Paper page
- Syvanen S, Xie R, Sahin S, Hammarlund-Udenaes M. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res. 2006;23(4):705–17. · DOI
- Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. 2007;24(5):1014–25. · DOI · Paper page
- Jeffrey P, Summerfield SG. Challenges for blood-brain barrier (BBB) screening. Xenobiotica. 2007;37(10–11):1135–51. · DOI
- Hammarlund-Udenaes M, Bredberg U, Friden M. Methodologies to assess brain drug delivery in lead optimization. Curr Top Med Chem. 2009;9(2):148–62. · DOI
- Syvanen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, Knudsen GM, Hammarlund-Udenaes M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37(3):635–43. · DOI · Paper page
- Cui Y, Lotz R, Rapp H, Klinder K, Himstedt A, Sauer A. Muscle to brain partitioning as measure of transporter-mediated efflux at the rat blood-brain barrier and its implementation into compound optimization in drug discovery. Pharmaceutics. 2019;11(11):595. · DOI
- Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang S-M, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ, Consortium IT. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther. 2013;94(1):80–94. · DOI · Paper page
- Zhang M-Y, Kerns E, McConnell O, Sonnenberg-Reines J, Zaleska MM, Steven Jacobsen J, Butera J, Kreft A. Brain and plasma exposure profiling in early drug discovery using cassette administration and fast liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2004;34(2):359–68. · doi:10.1016/s0731-7085(03)00523-5
- Kitamura A, Okura T, Higuchi K, Deguchi Y. Cocktail-dosing microdialysis study to simultaneously assess delivery of multiple organic-cationic drugs to the brain. J Pharm Sci. 2016;105(2):935–40. · doi:10.1002/jps.24691
- Moya ELJ, Vandenhaute E, Rizzi E, Boucau MC, Hachani J, Maubon N, Gosselet F, Dehouck MP. Miniaturization and automation of a human in vitro blood-brain barrier model for the high-throughput screening of compounds in the early stage of drug discovery. Pharmaceutics. 2021;13(6):892. · DOI
- Trapa PE, Troutman MD, Lau TY, Wager TT, Maurer TS, Patel NC, West MA, Umland JP, Carlo AA, Feng B, Liras JL. In vitro–in vivo extrapolation of key transporter activity at the blood-brain barrier. Drug Metab Dispos. 2019;47(4):405–11. · DOI
- Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T, Wagner B, Draganov D, Vazvaei F, Donzelli M, Paehler A, Merchant M, Yu L. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol. 2020;22(6):819–29. · DOI
- Graham TH, Shen HC, Liu W, Xiong Y, Verras A, Bleasby K, Bhatt UR, Chabin RM, Chen D, Chen Q, Garcia-Calvo M, Geissler WM, He H, Lassman ME, Shen Z, Tong X, Tung EC, Xie D, Xu S, Colletti SL, Tata JR, Hale JJ, Pinto S, Shen D-M. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorg Med Chem Lett. 2012;22(1):658–65. · doi:10.1016/j.bmcl.2011.10.060
- Braun C, Sakamoto A, Fuchs H, Ishiguro N, Suzuki S, Cui Y, Klinder K, Watanabe M, Terasaki T, Sauer A. Quantification of transporter and receptor proteins in dog brain capillaries and choroid plexus: relevance for the distribution in brain and CSF of selected BCRP and P-gp substrates. Mol Pharm. 2017;14(10):3436–47. · DOI
- Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579–88. · DOI
- Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–45. · DOI · Paper page
- Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161–6. · DOI · Paper page
- Fenstermacher J, Patlak C. CNS, CSF, and extradural fluid uptake of various hydrophilic materials in the dogfish. Am J Physiol Regul Integr Comp Physiol. 1977;232(1):R45–53. · doi:10.1152/ajpregu.1977.232.1.r45
- Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004;56(12):1825–57. · DOI · Paper page
- de Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40(3):315–26. · DOI · Paper page
- Saleh MAA, Loo CF, Elassaiss-Schaap J, De Lange ECM. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations. J Pharmacokinet Pharmacodyn. 2021;48(5):725–41. · DOI
- Fischer H, Senn C, Ullah M, Cantrill C, Schuler F, Yu L. Calculation of an apical efflux ratio from P-Glycoprotein (P-gp) in vitro transport experiments shows an improved correlation with in vivo cerebrospinal fluid measurements in rats: impact on P-gp screening and compound optimization. J Pharmacol Exp Ther. 2021;376(3):322–9. · doi:10.1124/jpet.120.000158
- Trünkle C, Lechner C, Korr D, Bouché L, Barak N, Fernández-Montalván A, Süssmuth RD, Reichel A. Concentration dependence of the unbound partition coefficient Kp(uu) and its application to correct for exposure-related discrepancies between biochemical and cellular potency of KAT6A inhibitors. Drug Metab Dispos. 2020;48(7):553–62. · DOI
- Mateus A, Gordon LJ, Wayne GJ, Almqvist H, Axelsson H, Seashore-Ludlow B, Treyer A, Matsson P, Lundback T, West A, Hann MM, Artursson P. Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Proc Natl Acad Sci U S A. 2017;114(30):E6231–9. · DOI · Paper page
- Di L, Riccardi K, Tess D. Evolving approaches on measurements and applications of intracellular free drug concentration and Kpuu in drug discovery. Expert Opin Drug Metab Toxicol. 2021;17(7):733–46. · DOI
- Orozco CC, Atkinson K, Ryu S, Chang G, Keefer C, Lin J, Riccardi K, Mongillo RK, Tess D, Filipski KJ, Kalgutkar AS, Litchfield J, Scott D, Di L. Structural attributes influencing unbound tissue distribution. Eur J Med Chem. 2020;185:111813. · DOI
- Riccardi K, Lin J, Li Z, Niosi M, Ryu S, Hua W, Atkinson K, Kosa RE, Litchfield J, Di L. Novel method to predict in vivo liver-to-plasma K(puu) for OATP substrates using suspension hepatocytes. Drug Metab Dispos. 2017;45(5):576–80. · DOI
- Zhang D, Hop C, Patilea-Vrana G, Gampa G, Seneviratne HK, Unadkat JD, Kenny JR, Nagapudi K, Di L, Zhou L, Zak M, Wright MR, Bumpus NN, Zang R, Liu X, Lai Y, Khojasteh SC. Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. Drug Metab Dispos. 2019;47(10):1122–35. · DOI
- Delgado-Lopez PD, Corrales-Garcia EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–71. · DOI · Paper page
- Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes J, Hughes GD, MacFaul PA, Mulholland KR, McGuire TM, Ouvry G, Pass M, Robb G, Stratton N, Wang Z, Wilson J, Zhai B, Zhao K, Al-Huniti N. The identification of potent, selective, and orally available inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). J Med Chem. 2018;61(9):3823–41. · DOI
- Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, Gavine P, Cui A, Ling S, Stott J, Clark R, Peel S, Gill P, Goodwin LM, Smith A, Pike KG, Barlaam B, Pass M, O’Connor MJ, Smith G, Cadogan EB. Pharmacology of the ATM Inhibitor AZD0156: potentiation of irradiation and Olaparib responses preclinically. Mol Cancer Ther. 2020;19(1):13–25. · DOI · Paper page
- Reddy VP, Sykes A, Colclough N, Durant ST, o Connor LO, Hoch M, Bruna NB, Vita S, Merchant MS, Pass M. Abstract 4868: A preclinical PK/PD model based on a mouse glioblastoma survival model for AZD1390, a novel, brain-penetrant ATM kinase inhibitor, to predict the inhibition of DNA damage response induced by radiation and the human efficacious dose. 2019. · doi:10.1158/1538-7445.am2019-4868
Cited by
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03574-1 · Cited by 19
“Currently, Kp,uu has been regarded as a “game changing parameter” in the pharmaceutical industry and is widely accepted in the decision making process in the selection of candidates for further development and prediction of an effective therapeutic dose [98].”
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0217 · Cited by 8
Teichman, E. M., Hu, J., Lin, H.-Y., Fisher-Foye, R. L., Blando, A., Hu, X., Kaniskan, H. Ü., Montgomery, S. E., Cai, M., Parise, L. F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02972-8 · Cited by 5
Metadata
- Authors
- Loryan, I., Reichel, A., Feng, B., Bundgaard, C., Shaffer, C., Kalvass, C., Bednarczyk, D., Morrison, D., Lesuisse, D., Hoppe, E., Terstappen, G. C., Fischer, H., Di, L., Colclough, N., Summerfield, S., Buckley, S. T., Maurer, T. S., & Fridén, M.
- Venue
- Pharmaceutical Research
- Published
- 2022-04-11
- Volume
- 39
- Issue
- 7
- Pages
- 1321-1341
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W4223488441
- Cited by
- 142
- References
- 6
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Uppsala University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development. https://app.cochat.ai/papers/10.1007/s11095-022-03246-6
- The paper
- Loryan, I., Reichel, A., Feng, B., Bundgaard, C., Shaffer, C., Kalvass, C., Bednarczyk, D., Morrison, D., Lesuisse, D., Hoppe, E., Terstappen, G. C., Fischer, H., Di, L., Colclough, N., Summerfield, S., Buckley, S. T., Maurer, T. S., & Fridén, M. (2022). Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development. Pharmaceutical Research. https://doi.org/10.1007/s11095-022-03246-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.